Merck posts Q3 2026 results with oncology approvals and new sac-TMT regulatory filingOct 29Quarterly updateGilead SciencesMerck & Co., Inc.
Kite's ZUMA-2 Cohort 3 trial in BTKi-naive mantle cell lymphoma completes, results postedAug 18Trial updatebrexucabtagene autoleucelFludarabine